We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rifampicin treatment of canine pyoderma due to multidrug-resistant meticillin-resistant staphylococci: a retrospective study of 32 cases.
- Authors
De Lucia, Michela; Bardagi, Mar; Fabbri, Elisabetta; Ferreira, Diana; Ferrer, Lluis; Scarampella, Fabia; Zanna, Giordana; Fondati, Alessandra
- Abstract
Background Rifampicin has received increased interest in veterinary dermatology because of its activity against multidrug-resistant meticillin-resistant staphylococci ( MRS). There is limited knowledge about the efficacy and safety of rifampicin in dogs. Hypothesis/Objective To provide information on response to treatment and adverse effects in dogs treated with rifampicin for multidrug-resistant MRS pyoderma. Animals Thirty two dogs treated with rifampicin for rifampicin-susceptible multidrug-resistant MRS pyoderma. Methods Retrospective review of medical records, including alanine aminotransferase ( ALT) and alkaline phosphatase ( ALP) serum activity levels and total bilirubin concentrations, obtained before and throughout the treatment, was performed. Results Oral rifampicin as sole systemic antimicrobial therapy (median dose 5 mg/kg twice daily) was effective in 71.88% of cases. Topical antimicrobials were used in most cases. Median duration of rifampicin treatment was five weeks for superficial pyoderma and four weeks for deep pyoderma. Gastrointestinal signs were reported in 15% of treated dogs. Statistically significant increases of ALT ( P = 0.045) and ALP ( P = 0.0002) values after 3-4 weeks of treatment was observed. The median increase was equal to 0.3 and ×1.5 the upper limit of the reference ranges for ALT and ALP, respectively. Conclusions/Clinical importance Oral rifampicin combined with topical antimicrobials can be considered an effective therapeutic option for canine superficial and deep pyoderma caused by rifampicin-susceptible multidrug-resistant MRS. Liver enzyme induction might be the most important cause of ALT and ALP increase associated with rifampicin therapy in dogs.
- Subjects
RIFAMPIN; MULTIDRUG resistance; METHICILLIN-resistant staphylococcus aureus; DOG diseases; VETERINARY therapeutics; ALANINE aminotransferase; ALKALINE phosphatase; BILIRUBIN
- Publication
Veterinary Dermatology, 2017, Vol 28, Issue 2, p171
- ISSN
0959-4493
- Publication type
Article
- DOI
10.1111/vde.12404